Agios Pharmaceuticals (AGIO) Shares are Down -0.4%

Agios Pharmaceuticals (AGIO) has risen sharply, recording gains of 45.31% in the past 4 weeks. However, the stock has corrected -0.4% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 46.09% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 11.72% and the 50-Day Moving Average is 20.76%.The 200 Day SMA reached 14.38%


Agios Pharmaceuticals (NASDAQ:AGIO): After opening at $52.2, the stock dipped to an intraday low of $51.89 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $53.43 and the buying power remained strong till the end. The stock closed at $52.82 for the day, a gain of 1.93% for the day session. The total traded volume was 572,759. The stocks close on the previous trading day was $52.82.

Agios Pharmaceuticals (AGIO) stock is expected to deviate a maximum of $15.71 from the average target price of $64.8 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $90 and the most muted being $49.

Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.